{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
beta carotene
to a specific field?
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Nisterime is a dihydrotestosterone derivative. Nisterime acetate (ORF-9326) was shown to inhibit implantation in several species. It is also interrupts the postimplantation stage of gestation.
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Iodophthalein was used as an iodine-containing X-ray contrast agent in icteric subjects. There is also existed mention, that iodophthalein has also been used as a wound treatment, and for the treatment of intestinal catarrhs. But nowadays more modern drugs are being used.
Status:
Investigational
Source:
NCT04523870: Not Applicable Interventional Completed Healthy
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
JAN:DEQUALINIUM SALYCILATE [JAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Dequalinium salicylate is a bisquanternary quinolinium antiseptic which kills many gram-positive and gram-negative bacteria. Dequalinium Salicylate have antibacterial (mediated by Dequalinium action) and anti-inflammatory activities (mediated by Salicylic acid action). Dequalinium has an antiseptic effect against a wide range of bacteria, yeasts, and some fungi and viruses. It kills the micro-organisms associated with various mild infections of the mouth and throat. Salicylic acid have direct anti-inflammatory activity mediated by inhibition of both types of cyclo-oxygenases (COX-1 and COX-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid.
Status:
Investigational
Source:
NCT03117920: Phase 2 Interventional Completed Pancreatic Cancer
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Omtriptolide (previously known as PG490-88 or F60008), an immunosuppressant that has been shown to be the safe and potent antitumor agent and it has been approved entry into Phase I clinical trial for the treatment of prostate cancer in the USA. In addition, the drug is participating in phase I clinical trial for the treatment of myeloid leukemia. Experiments on animals have shown omtriptolide was highly effective in the prevention of murine graft-versus-host disease (GVHD). The immunosuppressive effect of the drug was mediated by inhibition of alloreactive T cell expansion through interleukin-2 production. However, this study was discontinued. Recently published article has shown omtriptolide possesses the potential as a prophylactic agent to prevent ischemia/reperfusion (I/R)-induced lung injury.
Status:
Investigational
Source:
NCT04590508: Phase 2 Interventional Active, not recruiting Crohn Disease
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Xanthohumol is a prenylated flavonoid most abundant in hops. It is found in beers and refreshment drinks. It can attenuate several factors of the metabolic syndrome. It has been reported to inhibit adipogenesis or increase cell apoptosis and therefore can be used in preventing obesity. Xanthohumol inhibited angiogenesis by suppressing NF-κB activity in pancreatic cancer. Xanthohumol may represent a novel therapeutic agent for the management of pancreatic cancer. Moreover, it is in phase I clinical trials for preventing many types of cancer. It has a range of other biological properties: antiviral, antimalarial, antibacterial and as an osteoporosis preventing agent.
Status:
Investigational
Source:
NCT00129194: Phase 1 Interventional Completed HIV Infections
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
KP-1461 is a prodrug of KP-1212, an antiviral agent developed for the treatment of human immunodeficiency virus (HIV) infection. KP-1212 induces an increase in the HIV mutation rate thus leading to viral ablation.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Orpanoxin (previously known as F-776), a nonsteroidal anti-inflammatory drug that was developed as an analgesic agent. Orpanoxin is a prostaglandin synthetase inhibitor and may have a potential for the treatment of rheumatic. However, information about the current development of this drug is not available.
Status:
Investigational
Source:
NCT03594058: Phase 2 Interventional Completed Overactive Bladder
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Solabegron (GW427353), a beta-3 adrenoceptor agonist, is in development with AltheRx (now Velicept Therapeutics) for the treatment of irritable bowel syndrome (IBS) and overactive bladder (OAB). Solabegron was discovered and first developed by GlaxoSmithKline. It was acquired by AltheRx, which merged with Velicept in 2015 to continue development of the program. Solabegron has been tested in over 800 study subjects in a twice-a-day formulation and demonstrated efficacy in the treatment of OAB as well as IBS. A once daily formulation designed to optimize patient convenience as well as efficacy has been developed and is currently being evaluated in a phase 2b dose ranging clinical trial. A Phase 2b dose ranging study with the twice daily formulation also began enrollment in Q1 2018.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Sergolexole [LY 281067] is an ergoline ester similar in structure to amesergide [LY 237733], with potent and highly selective antagonist activity at serotonin 2. The preclinical pharmacologic activity of LY 281067 shows it to be a potent and highly selective serotonergic (5-HT2) receptor antagonist. Based upon binding studies with 5-HT2 receptors in brain cortical membranes and block of 5-HT-induced contractions in the rat jugular vein, LY 281067 showed high affinity at 5-HT2 receptors with a dissociation constant of approximately 1 nM. LY 281067 was a highly selective 5-HT2 receptor antagonist without appreciably binding to 5-HT1, D1 or D2 receptors or interacting with histamine (H1), cholinergic, beta adrenergic or alpha-1 adrenergic receptors in smooth muscle. LY 281067 had modest affinity at alpha-2 receptors with a dissociation constant of approximately 100 nM. Oral bioavailability of LY 281067 in spontaneously hypertensive rats was excellent with an oral to i.v. dose ratio approximating 4. Sergolexole was undergoing phase II clinical trials with Eli Lilly in the USA as a potential treatment for migraine and anxiety, but development of this compound, but development of this compound has been discontinued.
